{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:03:59Z","timestamp":1779689039433,"version":"3.53.1"},"reference-count":38,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Pediatric tuberculosis (TB) remains a major global health concern, accounting for a substantial proportion of TB-related morbidity and mortality worldwide. Treatment in children is particularly challenging due to age-specific pharmacokinetics, difficulties in drug administration, poor palatability, and reliance on caregivers for adherence. Objectives: This narrative review aims to evaluate the advantages and limitations of fixed-dose combinations (FDCs) in the treatment of pediatric TB, with a focus on adherence, pharmacological considerations, clinical outcomes, and implementation challenges. Methods: A narrative review of the literature was conducted, including clinical studies, pharmacokinetic analyses, programmatic data, and international guidelines related to the use of FDCs in pediatric TB management. Results: Evidence indicates that pediatric FDCs significantly improve treatment adherence by reducing pill burden and simplifying dosing regimens. They also decrease the risk of medication errors and inadvertent monotherapy, thereby contributing to the prevention of drug resistance. The availability of dispersible, child-friendly formulations has enhanced acceptability and ease of administration. However, limitations persist, including reduced flexibility in dose individualization, challenges in identifying the causative agent in adverse drug reactions, and variable access across settings. Pharmacokinetic concerns, particularly regarding rifampicin exposure, have been addressed in newer WHO-recommended formulations. Conclusions: FDCs represent a critical advancement in pediatric TB management and are strongly supported by international guidelines. Further research is needed to optimize formulations, ensure equitable access, and evaluate long-term clinical outcomes in diverse pediatric populations.<\/jats:p>","DOI":"10.3390\/ph19060806","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:33:54Z","timestamp":1779687234000},"page":"806","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fixed Dose Combinations as an Advantage for the Treatment of Pediatric Tuberculosis: A Narrative Review"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-2837","authenticated-orcid":false,"given":"Susanna","family":"Esposito","sequence":"first","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Rita","family":"Campana","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia Giorgia","family":"Arnesano","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-5568","authenticated-orcid":false,"given":"Nicola","family":"Principi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025). WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment and Care, World Health Organization."},{"key":"ref_2","unstructured":"World Health Organization (2025). WHO Consolidated Operational Handbook on Tuberculosis: Module 4: Treatment and Care, World Health Organization."},{"key":"ref_3","unstructured":"World Health Organization (2023). Roadmap Towards Ending TB in Children and Adolescents, World Health Organization. [3rd ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2001727","DOI":"10.1183\/13993003.01727-2020","article-title":"Epidemic and pandemic viral infections: Impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC)","volume":"56","author":"Ong","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Galli, L., Lancella, L., Tersigni, C., Venturini, E., Chiappini, E., Bergamini, B.M., Codifava, M., Venturelli, C., Tosetti, G., and Marabotto, C. (2016). Pediatric Tuberculosis in Italian Children: Epidemiological and Clinical Data from the Italian Register of Pediatric Tuberculosis. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17060960"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(16)30132-3","article-title":"Global burden of drug-resistant tuberculosis in children: A mathematical modelling study","volume":"16","author":"Dodd","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0140-6736(14)60195-1","article-title":"Incidence of multidrug-resistant tuberculosis disease in children: Systematic review and global estimates","volume":"383","author":"Jenkins","year":"2014","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5588\/ijtld.15.0471","article-title":"Counting children with tuberculosis: Why numbers matter","volume":"19","author":"Seddon","year":"2015","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1016\/S2214-109X(17)30289-9","article-title":"The global burden of tuberculosis mortality in children: A mathematical modelling study","volume":"5","author":"Dodd","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijid.2023.04.006","article-title":"World Tuberculosis Day 2023 theme \u201cYes! We Can End TB!\u201d","volume":"130","author":"Goletti","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_11","first-page":"392","article-title":"The natural history of childhood intra-thoracic tuberculosis: A critical review of literature from the pre-chemotherapy era","volume":"8","author":"Marais","year":"2004","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/civ581","article-title":"Clinical case definitions for classification of intrathoracic tuberculosis in children: An update","volume":"61","author":"Graham","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1086\/651490","article-title":"Pediatric tuberculosis: Global overview and challenges","volume":"50","author":"Swaminathan","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","first-page":"908","article-title":"Clinical case definitions for classification of intrathoracic tuberculosis in children","volume":"12","author":"Graham","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1080\/14656566.2020.1781091","article-title":"How does one choose the appropriate pharmacotherapy for children with lower respiratory tract infections?","volume":"21","author":"Esposito","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1097\/INF.0000000000003877","article-title":"QuantiFERON-TB Gold Plus Performance in Children: A Narrative Review","volume":"42","author":"Buonsenso","year":"2023","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(15)00095-8","article-title":"Xpert MTB\/RIF assay for the diagnosis of pulmonary tuberculosis in children: A systematic review and meta-analysis","volume":"3","author":"Detjen","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_18","unstructured":"World Health Organization (2022). WHO Operational Handbook on Tuberculosis. Module 5: Management of Tuberculosis in Children and Adolescents, World Health Organization."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prrv.2007.04.001","article-title":"Old and new drugs for the treatment of tuberculosis in children","volume":"8","author":"Donald","year":"2007","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_20","first-page":"143","article-title":"Challenges of tuberculosis treatment in children and adolescents","volume":"36","author":"Schaaf","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40272-015-0155-z","article-title":"Recommendations Concerning the First-Line Treatment of Children with Tuberculosis","volume":"18","author":"Principi","year":"2016","journal-title":"Paediatr. Drugs"},{"key":"ref_22","first-page":"614","article-title":"Isoniazid pharmacokinetics in children treated for respiratory tuberculosis","volume":"94","author":"McIlleron","year":"2009","journal-title":"Arch. Dis. Child."},{"key":"ref_23","first-page":"1106","article-title":"Rifampicin serum levels in childhood tuberculosis","volume":"13","author":"Thee","year":"2009","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_24","first-page":"1875","article-title":"Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculosis meningitis trials","volume":"67","author":"Svensson","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","first-page":"559","article-title":"Dosing strategies for optimizing pediatric tuberculosis treatment","volume":"53","author":"Zvada","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_26","first-page":"870","article-title":"Pharmacokinetics of first-line drugs in children with tuberculosis","volume":"21","author":"Chabala","year":"2017","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_27","first-page":"1115","article-title":"Pharmacokinetics of first-line antituberculosis drugs in children","volume":"61","author":"Draper","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2104535","article-title":"Shorter treatment for nonsevere tuberculosis in African and Indian children","volume":"386","author":"Turkova","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_29","first-page":"1329","article-title":"Quality assurance of pediatric anti-tuberculosis fixed-dose combinations","volume":"22","author":"Court","year":"2018","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_30","unstructured":"Lienhardt, C., Nahid, P., Rich, M.L., Bansal, A., Cole, S.T., Fielding, K., Murray, M., and Nunn, A.J. (2016). Target regimen profiles for treatment of tuberculosis: A WHO document. PLoS Med., 13."},{"key":"ref_31","first-page":"384","article-title":"Treatment and outcomes in children with multidrug-resistant tuberculosis","volume":"67","author":"Harausz","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1473-3099(15)00007-9","article-title":"Towards early inclusion of children in tuberculosis drugs trials: A consensus statement","volume":"15","author":"Nachman","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ajayi, T.O., Poka, M.S., and Witika, B.A. (2024). Nanotechnological innovations in paediatric tuberculosis management: Current trends and future prospects. Front. Drug Deliv., 3.","DOI":"10.3389\/fddev.2023.1295815"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kumar, M., Virmani, T., Kumar, G., Deshmukh, R., Sharma, A., Duarte, S., Brand\u00e3o, P., and Fonte, P. (2023). Nanocarriers in tuberculosis treatment: Challenges and delivery strategies. Pharmaceuticals, 16.","DOI":"10.3390\/ph16101360"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Shao, L., Shen, S., and Liu, H. (2022). Recent advances in PLGA micro\/nanoparticle delivery systems as novel therapeutic approach for drug-resistant tuberculosis. Front. Bioengin. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.941077"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e0008823","DOI":"10.1128\/cmr.00088-23","article-title":"Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: Recent developments","volume":"36","year":"2023","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1039\/D4MA01121J","article-title":"Isoniazid-loaded multicore magnetic nanoparticles as a facile intervention for combating mycobacterial infection","volume":"6","author":"Panigrahi","year":"2025","journal-title":"Mater. Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12247-025-10030-7","article-title":"Formulation, in vitro characterization and anti-tuberculosis investigation of isoniazid nanocapsules","volume":"20","author":"Ezegbe","year":"2025","journal-title":"J. Pharm. Innov."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/806\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:36:01Z","timestamp":1779687361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060806"],"URL":"https:\/\/doi.org\/10.3390\/ph19060806","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}